Jun 16, 2026Amended0001213900-26-069143
All companies
Start with eToroTarsier Pharma files for 5M share NYSE IPO at $8-$10/sh Tarsier Pharma files for IPO with NYSE listing application Tarsier Pharma files for proposed NYSE IPO Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO
Tarsier Pharma Ltd
TARXIPO Upcoming
IPO UpcomingUnited States0 markets
Official IPO
Filed· Listing market: United StatesExpected IPO date
Apr 21, 2026
Final IPO price
To be announced
Shares offered
To be announced
IPO raise
$57.5M
Sources: sec-edgar, sec-harvest, nasdaq
No live market is quoted for Tarsier Pharma Ltd yet. Get in line for IPO-day access through a broker in the meantime.
eToro
Invest in stocks once they list with eToro
Trade stocks, ETFs and crypto from one simple account.
About Tarsier Pharma Ltd
Tarsier Pharma Ltd is An investment in its company generally involves complex tax considerations.
What the company does
- No taxing authority in any jurisdiction has reviewed the transactions described herein, and any taxing authority may take different positions than the ones contemplated by.
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
Business profile
Tarsier Pharma Ltd belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
AmendedEDGAR filings resolved from TARX / CIK 0002102720.
Jun 8, 2026Amended0001213900-26-066188
May 18, 2026Free writing prospectus0001213900-26-058483
May 18, 2026Amended0001213900-26-058235
Apr 21, 2026Filed0001213900-26-046063
DRS/Afilename1.htm
Mar 31, 2026Confidential draft0001213900-26-036943
DRS/Afilename1.htm
Feb 24, 2026Confidential draft0001213900-26-019853
Dec 29, 2025Confidential draft0001213900-25-125843
Latest Tarsier Pharma Ltd IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
Investing.comJun 8, 2026IPO filing
IPO filing update specifying share count (5M) and the $8–$10 per-share range.
Investing.comMay 18, 2026IPO filing
Reports Tarsier Pharma’s filing for a proposed NYSE IPO and provides the indicative price range and listing/ticker details.
Investing.comApr 21, 2026IPO filing
IPO-related filing news for Tarsier Pharma, including the underwriter and company description context.
Renaissance Capital (IPO Center)Apr 21, 2026IPO context
IPO filing context (SEC filing to raise up to ~$35M), including target listing venue/symbol and basic deal/background info.
Tarsier Pharma Ltd IPO — frequently asked questions
- When is Tarsier Pharma Ltd's IPO?
- Tarsier Pharma Ltd's IPO is currently expected around Apr 21, 2026. IPO dates can move until the company files and prices the offering, so we keep this page updated as new details are confirmed.
- What is Tarsier Pharma Ltd's expected IPO price?
- Tarsier Pharma Ltd's IPO price has not been set yet. The price range is usually disclosed in the final prospectus, shortly before the company lists.
- Is Tarsier Pharma Ltd publicly traded?
- Not yet — Tarsier Pharma Ltd is still a private company, so its shares aren't available on public exchanges. IPO Tracker monitors pre-IPO markets, IPO filings and the IPO calendar, so Tarsier Pharma Ltd's pre-IPO price and IPO date will appear here as soon as they're available.